This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics
Business

Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics

Editorial Board Published January 28, 2022
Share
Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics
SHARE

Biogen Inc. BIIB -0.30% is selling its share in biosimilar joint venture Samsung Bioepis for at least $2.25 billion to partner Samsung Biologics, 207940 3.79% adding to its cash pile after the disappointing launch of its Alzheimer’s disease drug Aduhelm.

Biogen and Samsung Biologics created Samsung Bioepis in 2012 to develop, manufacture and market biosimilar drugs, lower-priced copies of drugs made from living cells, including the rheumatoid-arthritis treatments Enbrel and Humira.

Biogen, based in Cambridge, Mass., owns a nearly 50% stake in the joint venture.

Under terms of the agreement announced late Thursday, Biogen will receive $1 billion in cash upon closing and then two payments of $812.5 million on the first anniversary of the closing and $437.5 million on the second anniversary of the closing.

Biogen is also eligible to receive up to $50 million contingent on reaching certain commercial milestones, Biogen said.


Newsletter Sign-up

In Today’s Paper

A complete list, with links, of every article from the day’s Journal.


Lawmakers and patient groups have looked for biosimilars to help lower costs for prescription drugs, like Humira and Enbrel, costing tens of thousands dollars a year.

Yet the copies, which were first authorized under the Affordable Care Act, haven’t been priced for as much of a discount as supporters expected and haven’t sold as much as anticipated. However, some analysts forecast higher uptake, as more drugs like big-selling Humira are copied.

Most of Samsung Bioepis’s biosimilar sales are in Europe.

The deal would give Biogen cash to make new acquisitions, as it grapples with the fallout over Aduhelm. Earlier this month, the agency overseeing Medicare issued a draft decision that it would pay for the drug only for patients in clinical trials, a move likely to severely restrict the numbers of patients receiving the drug.

Investors were shocked to learn that Biogen now plans to pursue regulatory approval for the experimental Alzheimer’s disease drug they previously pulled the plug on. But Heard on the Street’s Charley Grant explains why the optimism may be premature. Photo: Brian Snyder/Reuters

During a meeting with analysts this month, Chief Executive Michel Vounatsos said Biogen was working closely with its board to consider “strategic options” in the wake of the Medicare draft decision.

In December, Biogen said it was planning to cut costs by $500 million.

Through Thursday’s close, Biogen shares had fallen 46.2% over the past 12 months.

Biogen has a 50-50 profit split with Samsung on its biosimilar venture. In the first nine months of 2021, the company reported $610.2 million in biosimilar product revenue, all of it from outside the U.S. The companies plan to start selling their first U.S. biosimilar, for the vision-loss drug Lucentis, later this year.

Biogen didn’t say when it expected the transaction to close. After the deal closes, Biogen will continue to help sell the joint venture’s existing portfolio of biosimilars. A Biogen spokeswoman said that the company’s 50-50 profit split wouldn’t change.

Write to Joseph Walker at [email protected]

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Appeared in the January 28, 2022, print edition as ‘Biogen Cashes Out Biosimilars Interest.’

Contents
Newsletter Sign-upIn Today’s Paper
TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article Minnie Mouse debuts blue pantsuit on heels of green M&M makeover Minnie Mouse debuts blue pantsuit on heels of green M&M makeover
Next Article Robinhood’s Stock Is in Show-Me Mode Robinhood’s Stock Is in Show-Me Mode

Editor's Pick

Jordan Peterson Hospitalized, ‘Close to Loss of life’ Amid Weird Eating regimen, ‘A long time of Mould Publicity,’ Daughter Says

Jordan Peterson Hospitalized, ‘Close to Loss of life’ Amid Weird Eating regimen, ‘A long time of Mould Publicity,’ Daughter Says

Studying Time: 3 minutes Based on the most recent replace from his daughter, writer and psychologist Jordan Peterson is coping…

By Editorial Board 5 Min Read
Maggie Baugh: Every part We Know About Keith City’s Rumored New Girlfriend
Maggie Baugh: Every part We Know About Keith City’s Rumored New Girlfriend

Studying Time: 3 minutes Is Keith City hooking up together with his…

4 Min Read
Danielle Fishel Rebuffs Whitney Leavitt After ‘DWTS’ Gaffe
Danielle Fishel Rebuffs Whitney Leavitt After ‘DWTS’ Gaffe

Studying Time: 2 minutes Did Danielle Fishel simply put Whitney Leavitt in…

4 Min Read

Oponion

Dominant Rams makes themselves at residence in Arizona with rout of Vikings

Dominant Rams makes themselves at residence in Arizona with rout of Vikings

By Gary Klein, Los Angeles OccasionsGLENDALE, Ariz. — Now that’s what…

January 14, 2025

Regulators Back New Rules to Stop Criminals Using Crypto

Cryptocurrency firms could be forced to…

October 28, 2021

Dems assist pave manner for Donald J. Trump Avenue in Miami-Dade County after historic election victory

It’s an indication of the instances.…

December 4, 2024

Super Bowl Wagers Rise to Records as Online Sports Betting Sweeps U.S.

Gambling on the Super Bowl this…

February 15, 2022

Week 11 picks: Breaking down the Holy Warfare, Cal’s lengthy journey, Washington’s big problem and a key sport for Oregon State

The traits recommend Utah is the…

November 7, 2024

You Might Also Like

Russia for Business: Experts Who Help Drive Decisions
BusinessTrending

Russia for Business: Experts Who Help Drive Decisions

Amid sanctions and the restructuring of global supply chains, understanding the logic behind Russia’s actions has become a practical necessity…

4 Min Read
The Quiet Shift in America’s Workforce: Why Side Hustles Are Becoming Essential for Women Over 40
BusinessTrending

The Quiet Shift in America’s Workforce: Why Side Hustles Are Becoming Essential for Women Over 40

Across the nation, a quiet but powerful workforce shift is underway. Increasingly, women over 40 are seeking side hustles to…

4 Min Read
Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution
Business

Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution

At a time when billions of linked objects are reshaping industries, Thales has achieved a vital safety certification for its…

4 Min Read
Soracom IoT Platform Achieves SOC 2 Kind 2 Compliance for Safety, Availability, and Confidentiality
Business

Soracom IoT Platform Achieves SOC 2 Kind 2 Compliance for Safety, Availability, and Confidentiality

Soracom, Inc., right now introduced that it has efficiently achieved System and Group Controls (SOC) 2 Kind 2 compliance, reinforcing…

2 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?